• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在法布里病中使用双能X线吸收测定法评估骨质减少和骨质疏松症。

Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease.

作者信息

Shmara Alyaa, Lee Grace, Mgdsyan Mania, Hall Kathy, Sadri Nadia, Martin-Rios Angela, Valentine Kelsey, Kain Tatiana, Pahl Madeleine, Polgreen Lynda E, Kimonis Virginia

机构信息

Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine, 101 The City Drive South, ZC4482, Orange, CA, 92868, USA.

College of Osteopathic Medicine, Western University of Health Sciences, Pomona, CA, USA.

出版信息

Orphanet J Rare Dis. 2025 Apr 30;20(1):206. doi: 10.1186/s13023-025-03601-x.

DOI:10.1186/s13023-025-03601-x
PMID:40301993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12042328/
Abstract

BACKGROUND

Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD.

MATERIALS AND METHODS

To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California-Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results.

RESULTS

The average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores ≤ -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p =  < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications.

CONCLUSION

The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease.

摘要

背景

法布里病(FD)是一种罕见的多系统溶酶体贮积病,对心脏和肾脏影响最为显著。FD一种未得到充分认识的表现是骨矿物质密度降低。目前,对于FD患者的常规骨密度评估、骨质疏松症和骨质减少症的治疗,尚无具体指南。

材料与方法

为确定FD患者低骨矿物质密度的发生率,我们研究了2008年至2023年期间在加州大学欧文医学中心接受随访的25名患者的双能X线吸收测定(DXA)扫描结果,这些扫描是作为常规护理的一部分进行的。收集了12名男性和13名女性腰椎和股骨颈的最新骨密度结果,以检查低骨矿物质密度的患病率。选择腰椎或股骨颈的最低Z值和/或T值进行分析。在进行DXA扫描结果的同时(±9个月内)收集人口统计学因素、疾病和ERT状态以及其他实验室值,并与Z值和T值进行分析以评估相关性。在我们的队列中,平均年龄为51岁(中位数56岁,范围18 - 77岁)。分析了所有参与者的Z值以及绝经后女性和年龄≥50岁男性的T值,并将其与包括疾病持续时间、体重指数(BMI)、肾功能(通过估算肾小球滤过率[eGFR]测量)、血浆GL3、溶酶体GL3、钙、维生素D和碱性磷酸酶水平等各种指标进行相关性分析。这些参数与DXA扫描结果是同时获得的。

结果

所有参与者的平均Z值为 -1.2 ± 1.3(范围 -4.6至1.6)。所有参与者中有24%(n = 6)的Z值显著较低,≤ -2.0。为确定骨质减少(定义为T值在 -1.0至 -2.5之间)和骨质疏松(定义为T值 < -2.5)患者的发生率,对8名绝经后女性和7名50岁及以上男性的T值进行了分析。在这15名个体中,平均T值为 -2.2 ± 1.3(范围 -5.4至0.3),86.7%(n = 13)的结果异常(骨质减少和骨质疏松),53.3%(n = 8)患有骨质疏松症,33.3%(n = 5)患有骨质疏松症。我们发现男性(-1.98 ± 1.33)和女性患者(-.45 ± 0.82)的Z值存在显著差异,t(23) = 3.487(p = < 0.001)。我们未发现不同种族背景之间的Z值存在差异。Z值与溶酶体GL3水平之间存在强烈的负相关[r(15) = -.72,p = .001],Z值与体重指数(BMI)之间存在中度正相关[r(23) = .43,p = .033]。未发现Z值与钙水平之间存在相关性。T值与溶酶体GL3水平之间存在强烈的负相关[r(8) = -.86,p = .001],T值与DXA检查时参与者的年龄之间存在负相关[r(13) = -.57,p = 0.028]。T值与钙水平之间存在正相关[r(12) = .58,p = 0.030]。未观察到T值与BMI之间存在显著相关性。Z值或T值与疾病持续时间、ERT使用时间、肾功能(通过eGFR测量)、GL3、肌酐、碱性磷酸酶水平,或他们使用维生素D或同时使用的抗癫痫药物之间均无相关性。

结论

该队列研究结果突出了FD患者低骨矿物质密度的高发生率,以及低Z值和T值与溶酶体GL3水平升高和低钙水平之间的相关性。我们未发现与肾功能和维生素D水平之间存在相关性。我们讨论了法布里病中骨质减少/骨质疏松症的病因、预防和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/03df503d0034/13023_2025_3601_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/4d4863db6ea8/13023_2025_3601_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/84fe1333dea8/13023_2025_3601_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/03df503d0034/13023_2025_3601_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/4d4863db6ea8/13023_2025_3601_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/84fe1333dea8/13023_2025_3601_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7bf/12042328/03df503d0034/13023_2025_3601_Fig3_HTML.jpg

相似文献

1
Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease.在法布里病中使用双能X线吸收测定法评估骨质减少和骨质疏松症。
Orphanet J Rare Dis. 2025 Apr 30;20(1):206. doi: 10.1186/s13023-025-03601-x.
2
The value of calcaneal bone mass measurement using a dual X-ray laser Calscan device in risk screening for osteoporosis.应用双能 X 射线激光 Calscan 设备测量跟骨骨量在骨质疏松症风险筛查中的价值。
Clinics (Sao Paulo). 2009;64(8):757-62. doi: 10.1590/S1807-59322009000800008.
3
Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.慢性腹膜透析患者的骨矿物质密度及其与临床和实验室因素的相关性。
J Bone Miner Metab. 2006;24(1):79-86. doi: 10.1007/s00774-005-0650-3.
4
Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.健康沙特女性脊柱和股骨的骨矿物质密度:与维生素D状态、妊娠及哺乳的关系。
Calcif Tissue Int. 1999 Jul;65(1):23-8. doi: 10.1007/s002239900652.
5
Decreased trabecular bone score in patients affected by Fabry disease.法布里病患者的小梁骨评分降低。
J Endocrinol Invest. 2025 Jan;48(1):121-130. doi: 10.1007/s40618-024-02427-x. Epub 2024 Oct 3.
6
Diagnosis of low bone mass in CKD-5D patients.慢性肾脏病5期患者低骨量的诊断
Clin Nephrol. 2016 Feb;85(2):77-83. doi: 10.5414/CN108708.
7
Loss of bone mineral density in renal transplantation recipients.肾移植受者的骨矿物质密度丧失
Transplant Proc. 2010 Nov;42(9):3550-3. doi: 10.1016/j.transproceed.2010.07.106.
8
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.安大略省双能X线吸收法骨密度测定的应用:基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.
9
Comparison of bone mineral density with dual energy x-ray absorptiometry, quantitative ultrasound and single energy x-ray absorptiometry.双能X线吸收法、定量超声法和单能X线吸收法在骨密度测量中的比较。
Saudi Med J. 2005 Sep;26(9):1346-50.
10
Discordance in lumbar bone mineral density measurements by quantitative computed tomography and dual-energy X-ray absorptiometry in postmenopausal women: a prospective comparative study.绝经后妇女定量计算机断层扫描和双能 X 射线吸收法测定腰椎骨密度的不相符:一项前瞻性对比研究。
Spine J. 2023 Feb;23(2):295-304. doi: 10.1016/j.spinee.2022.10.014. Epub 2022 Nov 4.

本文引用的文献

1
Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease.肾脏活检对法布瑞病患儿何时开始酶替代治疗的影响。
Pediatr Nephrol. 2024 Jan;39(1):131-140. doi: 10.1007/s00467-023-06050-5. Epub 2023 Jul 20.
2
Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.法布瑞病患者骨矿物质密度的调查及酶替代疗法的变化。
Mol Genet Metab. 2023 Aug;139(4):107634. doi: 10.1016/j.ymgme.2023.107634. Epub 2023 Jun 27.
3
Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues.
法布里病中Globotriaosylceramide蓄积的临床相关性及β-半乳糖苷酶对受累组织的影响。
Mol Genet Metab. 2022 Dec;137(4):328-341. doi: 10.1016/j.ymgme.2022.10.005. Epub 2022 Oct 29.
4
Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with Fabry disease.法布瑞病患者的钙磷蛋白颗粒水平较高与髋骨骨密度降低有关。
Osteoporos Int. 2022 Aug;33(8):1783-1794. doi: 10.1007/s00198-022-06420-z. Epub 2022 May 16.
5
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.新型基于肌酐和胱抑素 C 的估算肾小球滤过率方程,无需考虑种族因素。
N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23.
6
Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience.意大利东北部法布里病的新生儿筛查:五年经验的结果。
Biomolecules. 2021 Jun 27;11(7):951. doi: 10.3390/biom11070951.
7
Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy.法布里病患者的可变临床特征及酶替代疗法的结果
Mol Genet Metab Rep. 2020 Dec 31;26:100700. doi: 10.1016/j.ymgmr.2020.100700. eCollection 2021 Mar.
8
Intermachine differences in DXA measurements vary by skeletal site, and impact the assessment of low bone density in children.双能X线吸收法(DXA)测量中的仪器间差异因骨骼部位而异,并影响儿童低骨密度的评估。
Bone. 2020 Dec;141:115581. doi: 10.1016/j.bone.2020.115581. Epub 2020 Aug 11.
9
Low bone mineral density due to secondary hyperparathyroidism in the mouse model of Fabry disease.法布里病小鼠模型中因继发性甲状旁腺功能亢进导致的低骨矿物质密度。
FASEB Bioadv. 2020 Jun 10;2(6):365-381. doi: 10.1096/fba.2019-00080. eCollection 2020 Jun.
10
Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis.法布里肾病的发病机制:纤维化的途径。
Mol Genet Metab. 2020 Feb;129(2):132-141. doi: 10.1016/j.ymgme.2019.10.010. Epub 2019 Oct 30.